Introducing the world’s only searchable, sortable database of cell and gene therapy manufacturing partners that is continuously updated.
A contract manufacturing organization (CMO) is a company that provides manufacturing services to cell and gene therapy companies on a contract basis. Contract development and manufacturing organizations (CDMOs) are similar, in that they offer services that include cell therapy product development, manufacturing, clinical trial support, and commercial supply.
Among cell and gene therapy companies, the pressure for manufacturing innovation and optimization can incentivize them to seek third-party partners who possess technical, manufacturing, and regulatory expertise, such as cell therapy contract manufacturing organizations.
Contract Manufacturing for Cell and Gene Therapies
Benefits of partnering with a cell or gene therapy therapy CDMO include scalability, speed to market, access to technical expertise without overhead costs, and cost efficiencies.
With 50+ companies now specializing in manufacturing and clinical trial support for cell and gene therapies, demand for these services is expanding.
In addition to industry giants that include Lonza, MaSTherCell S.A., WuXi, HCATS, and others, there are also specialty CDMOs entering the cell and gene therapy marketplace. For example, FUJIFILM Cellular Dynamics announced January 2019 that it is opening a $21M cGMP production facility to support its internal cell therapeutics pipeline, as well as serve as a CDMO for iPS cell products.
Similarly, Anemocyte announced itself as the first BMO, Biotech Manufacturing Organization, active in the field of cell and gene therapies. In addition to building out 2000 sq. metres of GMP and GMP-compliant facilities for the production of ATMP’s, its FLYn’ICE project will leverage drones equipped with cryogenic pods to maintain and monitor the temperature of cell and gene therapies (CGT) during transit.
On top of this activity, biotech industry behemoth Thermo Fisher Scientific snagged CGT CMO Brammer Bio for a price tag of $1.7 billion in March 2019 and Catalent Biologics acquired Paragon Bioservices for $1.2 billion in April 2019.
Clearly, cell and gene therapy CMO and CDMO market activity is accelerating.
Database of Cell and Gene Therapy CMOs / CDMOs
The goal of this database is to be the world’s only searchable, sortable database of cell and gene therapy manufacturing partners that is continuously updated on a daily basis.
Use it to identify potential manufacturing partners, or if you are a contract manufacturer, to identify the depth and breadth of your market competition.
This comprehensive database features:
- Name of company
- Description of cell and gene therapy manufacturing services
- Link to company’s CMO / CDMO services
Use it to:
1) Compare companies capable of manufacturing your cell or gene therapy product
2) Identify market competitors within the cell therapy CMO industry
3) Identify new market entrants offering CMO services
4) Spot countries with a high number of cell and gene therapy CMOs (“geographic hotspots”)
For a limited-time, you can claim the database for only $49 and have access for life.
Your product will be delivered instantly as an Excel download. Act soon, before this offer expires.
Of course, your investment is backed by our “Greater than 100%” Money Back Guarantee.